0
Lung Cancer: Late-Breaking Abstracts: Lung Cancer Mechanisms |

Imrecoxib Combined With Lobaplatin to Control Non-small Cell Lung Cancer Growth and Inhibit Invasion and Metastasis in an A549 Cell Nude Mice Xenograft Model FREE TO VIEW

Lingchan Wang, MMSc; Gang Chen, MD; Yunxia Zhao, MMSc; Dongchang Wang, MMSc
Author and Funding Information

Department of Respiratory Medicine 1, The Third Affiliated Hospital, Hebei Medical University, Shijiazhuang, China


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;149(4_S):A258. doi:10.1016/j.chest.2016.02.270
Text Size: A A A
Published online

SESSION TITLE: Late-Breaking Abstracts: Lung Cancer Mechanisms

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Sunday, April 17, 2016 at 08:30 AM - 09:30 AM

PURPOSE: To study whether imrecoxib can inhibit the growth, invasion, and metastasis of lung adenocarcinoma A549 cell xenografts in nude mice, and explore its mechanism as well as its efficacy when combined with lobaplatin.

METHODS: Lung adenocarcinoma A549 cells were subcutaneously injected into 30 male BALB/c nude mice, building a xenograft model. The mice were divided into 4 groups as follows: control, imrecoxib, lobaplatin, and imrecoxib combined with lobaplatin (combined). Tumor volumes were measured each week. The mice were sacrificed after 6.0 weeks and the xenograft tissues were removed. Hematoxylin and eosin staining was used to observe any pathological changes in tumor tissues in each group. Real-time polymerase chain reaction, immunohistochemistry, and flow cytometry were used to detect tumor ezrin and cortactin mRNA and their protein expression levels. The statistics were analyzed by one-way analysis of variance or non-parametric tests.

RESULTS: (1) Compared with the control group, tumor tissue volumes and weights in the imrecoxib and combined groups significantly decreased; however, necrosis areas increased. (2) Compared with the control group, ezrin and cortactin protein expression levels were significantly lower in the imrecoxib and combined groups. Compared with the control group, ezrin mRNA and cortactin mRNA expression levels were also significantly lower in the imrecoxib and combined groups. (3) A positive correlation was seen between ezrin protein and cortactin protein, as well as between ezrin mRNA and cortactin mRNA.

CONCLUSIONS: Imrecoxib could inhibit the growth, invasion and metastasis of non-small-cell lung cancer. The mechanism might be related to the downregulation of ezrin and cortactin proteins, promoting lung cancer cell apoptosis and increasing adhesion among the lung cancer cells. Imrecoxib could enhance sensitization to lobaplatin chemotherapy.

CLINICAL IMPLICATIONS: It is unclear at home and abroad whether COX-2 inhibitors combined with chemotherapy drugs can enhance the efficacy of chemotherapy. Imrecoxib may become a new target for inhibiting lung cancer invasion and metastasis, and a breakthrough in lung cancer treatment.

DISCLOSURE: The following authors have nothing to disclose: Lingchan Wang, Gang Chen, Yunxia Zhao, Dongchang Wang

No Product/Research Disclosure Information


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543